Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive Levetiracetam therapy

Journal of Clinical Neurology (Korea)

Volumn 7, Issue 3, 2011, Pages 128-136

  Lee, Jang Joon ^a   Song, Hyun Seok ^b   Hwang, Yang Ha ^b   Lee, Ho Won ^b   Suh, Chung Kyu ^b   Park, Sung Pa ^b  

^a Daegu Fatima Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Drug refractory; Epilepsy; Levetiracetam; Psychiatric symptoms; Quality of life; Suicide

Indexed keywords

EID: 80053448898     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2011.7.3.128     Document Type: Review

References (42)

1. Park SP, Song HS, Hwang YH, Lee HW, Suh CK, Kwon SH. Differential effects of seizure control and affective symptoms on quality of life in people with epilepsy. Epilepsy Behav 2010;18:455-459.
2. Lim HW, Song HS, Hwang YH, Lee HW, Suh CK, Park SP, et al. Predictors of suicidal ideation in people with epilepsy living in Korea. J Clin Neurol 2010;6:81-88.
3. Cramer JA, Blum D, Fanning K, Reed M; Epilepsy Impact Project Group. The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy Behav 2004;5:337-342.
4. Mula M, Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 2009;11:1-9.
5. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. Early development of intractable epilepsy in children: a prospective study. Neurology 2001;56:1445-1452.
6. Nilsson L, Ahlbom A, Farahmand BY, Asberg M, Tomson T. Risk factors for suicide in epilepsy: a case control study. Epilepsia 2002;43: 644-651.
7. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia 1997;38:353-362.
8. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53:S53-S67.
9. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
10. Heo K, Lee BI, Yi SD, Huh K, Kim JM, Lee SA, et al. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients. Seizure 2007;16:402-409.
11. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 2007; 13:57-78.
12. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101:9861-9866.
13. Muralidharan A, Bhagwagar Z. Potential of levetiracetam in mood disorders: a preliminary review. CNS Drugs 2006;20:969-979.
14. Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003;4:124-132.
15. Ciesielski AS, Samson S, Steinhoff BJ. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav 2006;9:424-431.
16. Mazza M, Martini A, Scoppetta M, Mazza S. Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:539-543.
17. Wu T, Chen CC, Chen TC, Tseng YF, Chiang CB, Hung CC, et al. Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy: an open-label multicenter study. Epilepsy Behav 2009;16:468-474.
18. Hurtado B, Koepp MJ, Sander JW, Thompson PJ. The impact of levetiracetam on challenging behavior. Epilepsy Behav 2006;8:588-592.
19. Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2007;10:105-110.
20. Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, et al. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 2007;10:296-303.
21. Mula M, Sander JW. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav 2007;11:130-132.
22. Mula M, Trimble MR, Sander JW. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 2007;48:2322-2326.
23. Helmstaedter C, Fritz NE, Kockelmann E, Kosanetzky N, Elger CE. Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav 2008;13:535-541.
24. Labiner DM, Ettinger AB, Fakhoury TA, Chung SS, Shneker B, Tatum Iv WO, et al. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 2009;50:434-442.
25. de la Loge C, Hunter SJ, Schiemann J, Yang H. Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav 2010;18:291-298.
26. Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010;75:335-340.
27. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. Early development of intractable epilepsy in children: a prospective study. Neurology 2001;56:1445-1452.
28. Kim ZS, Lee YS, Lee MS. Twoand four-subtest short forms of the Korean-Wechsler Adult Intelligence Scale. Seoul J Psychiatry 1994; 19:121-126.
29. Rhee MK, Lee YH, Jung HY, Choi JH, Kim SH, Kim YK, et al. A standardization study of Beck Depression Inventory (II): Korean version (K-BDI): validity. Korean J Psychopathol 1995;4:96-104.
30. YookSP, Kim ZS. A clinical study on the Korean version of Beck Anxiety Inventory: comparative study of patient and non-patient. Korean J Clin Psychol 1997;16:185-197.
31. Kim JH, Kim KI. The standardization study of symptom checklist90-revision in Korea III. Mental Health Res 1984;2:278-311.
32. Shin MS, Park KB, Oh KJ, Kim ZS. A study of suicidal ideation among high school students: the structural relation among depression, hopelessness, and suicidal ideation. Korean J Clin Psychol 1990;9:1-19.
33. Yoo HJ, Lee SA, Heo K, Kang JK, Ko RW, Yi SD, et al. The reliability and validity of Korean QOLIE-31 in patients with epilepsy. J Korean Epilepsy Soc 2002;6: 45-52.
34. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981;22:489-501.
35. Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005;28: 72-78.
36. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001;47: 77-90.
37. Arroyo S, Crawford P. Safety profile of levetiracetam. Epileptic Disord 2003;5 Suppl 1: S57-S63.
38. Harden C. Safety profile of levetiracetam. Epilepsia 2001;42 Suppl 4: 36-39.
39. Wolf P. Acute behavioral symptomatology at disappearance of epileptiform EEG abnormality. Paradoxical or "forced" normalization. Adv Neurol 1991;55:127-142.
40. Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality. 2008 May 23 [Accessed 2009 Dec 4]. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf.
41. Birbeck GL, Hays RD, Cui X, Vickrey BG. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002; 43:535-538.
42. Schmitz B. Effects of antiepileptic drugs on mood and behavior. Epilepsia 2006;47 Suppl 2:28-33.